January 17, 2017 08:06 AM EST

Biogen to pay $1.25B to de-risk a Tecfidera patent battle, and Forward Pharma’s shares rocket up

John Carroll

Editor & Founder

Biogen will pay Forward Pharma $1.25 billion in cash to help satisfy the Danish biotech’s claims that its flagship multiple sclerosis drug Tecfidera interfered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen to pay $1.25B to de-risk a Tecfidera patent battle, and Forward Pharma’s shares rocket up

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Bio­gen to pay $1.25B to de-risk a Tec­fidera patent bat­tle, and For­ward Phar­ma’s shares rock­et up

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Biogen to pay $1.25B to de-risk a Tecfidera patent battle, and Forward Pharma’s shares rocket up

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test